After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …

In this Review, we highlight some recent developments in the discovery and application of
broadly neutralizing antibodies (bnAbs) to human immunodeficiency virus (HIV); ie …

A SARS-CoV-2 variant carrying the Spike protein amino acid change D614G has become
the most prevalent form in the global pandemic. Dynamic tracking of variant frequencies …

The development of a protective vaccine remains a top priority for the control of the HIV/AIDS
pandemic. Here, we show that a messenger RNA (mRNA) vaccine co-expressing …

Long-lasting, latently infected resting CD4+ T cells are the greatest obstacle to obtaining a
cure for HIV infection, as these cells can persist despite decades of treatment with …

Human immunodeficiency virus (HIV) persists indefinitely in individuals with HIV who
receive antiretroviral therapy (ART) owing to a reservoir of latently infected cells that contain …

Recent efforts toward an HIV vaccine focus on inducing broadly neutralizing antibodies, but
eliciting both neutralizing antibodies (nAbs) and cellular responses may be superior. Here …

Natural antibodies (Abs) can target host glycans on the surface of pathogens. We studied
the evolution of glycan-reactive B cells of rhesus macaques and humans using glycosylated …

Passive administration of HIV neutralizing antibodies (nAbs) can protect macaques from
hard-to-neutralize (tier 2) chimeric simian-human immunodeficiency virus (SHIV) challenge …

The generation of HIV bnAbs may be one of the greatest feats of the human immune system
and our best hope of finally creating an HIV vaccine. The striking amount of somatic …